Final Revised Vaccine Information Materials for Serogroup B Meningococcal Vaccine, 62136-62137 [2016-21574]
Download as PDF
<![CDATA[
62136
Federal Register / Vol. 81, No. 174 / Thursday, September 8, 2016 / Notices
co-trustee of the Jason P. LaFrance GW
Investments Trust, and Jason P.
LaFrance, Little Rock, Arkansas, as cotrustee of the Jason P. LaFrance GW
Investments Trust and as trustee of the
Amy Beth LaFrance GW Investments
Trust and the Amy LaFrance Bancroft
GW Investments Revocable Trust, Little
Rock, Arkansas, and Daniel B. Andrews,
Sherwood, Arkansas; to acquire voting
shares of Greenwoods Financial Group,
Inc., Lake Mills, Wisconsin, and thereby
join the existing LaFrance Family
Control Group that was approved to
acquire 10 percent or more of the
outstanding shares of Greenwoods
Financial Group, Inc. Greenwoods
Financial Group, Inc. controls The
Greenwood’s State Bank, Lake Mills,
Wisconsin.
Comments on this application must
be received by September 16, 2016.
Board of Governors of the Federal Reserve
System, September 1, 2016.
Robert deV. Frierson,
Secretary of the Board.
President) 2200 North Pearl Street,
Dallas, Texas 75201–2272:
1. Andrew C. Rector, Fort Worth,
Texas, individually; and Andrew C.
Rector, Linda Lloyd Rector 2009
Irrevocable Trust, Tracy T. Rector 2009
Irrevocable Trust, Scott Willis Rector
2009 Irrevocable Trust, and Andrew
Campbell Rector 2009 Irrevocable Trust,
all of Fort Worth, Texas, and Kathy
Rector, Azle, Texas, as a group acting in
concert, to acquire shares of Horizon
Bankshares, Inc., and therefore
indirectly The National Bank of Texas at
Fort Worth, both of Fort Worth, Texas.
Board of Governors of the Federal Reserve
System, September 2, 2016.
Robert deV. Frierson,
Secretary of the Board.
[FR Doc. 2016–21596 Filed 9–7–16; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[FR Doc. 2016–21505 Filed 9–7–16; 8:45 am]
BILLING CODE 6210–01–P
[Docket No. CDC–2015–0059]
FEDERAL RESERVE SYSTEM
Final Revised Vaccine Information
Materials for Serogroup B
Meningococcal Vaccine
mstockstill on DSK3G9T082PROD with NOTICES
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
The notificants listed below have
applied under the Change in Bank
Control Act (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
notices are set forth in paragraph 7 of
the Act (12 U.S.C. 1817(j)(7)).
The notices are available for
immediate inspection at the Federal
Reserve Bank indicated. The notices
also will be available for inspection at
the offices of the Board of Governors.
Interested persons may express their
views in writing to the Reserve Bank
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than
September 23, 2016.
A. Federal Reserve Bank of Kansas
City (Dennis Denney, Assistant Vice
President) 1 Memorial Drive, Kansas
City, Missouri 64198–0001:
1. Robert Quintana, Las Vegas, New
Mexico; to acquire shares of FNB
Financial Corporation, and thereby
indirectly acquire Community 1st Bank
Last Vegas, both of Las Vegas, New
Mexico.
B. Federal Reserve Bank of Dallas
(Robert L. Triplett III, Senior Vice
VerDate Sep<11>2014
19:34 Sep 07, 2016
Jkt 238001
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
Under the National
Childhood Vaccine Injury Act (NCVIA)
(42 U.S.C. 300aa–26), CDC must develop
vaccine information materials that all
health care providers are required to
give to patients/parents prior to
administration of specific vaccines. On
October 14, 2015, CDC published a
notice in the Federal Register (80 FR
61819) seeking public comments on
proposed updated vaccine information
materials for meningococcal ACWY and
serogroup B meningococcal vaccines.
Following review of comments
submitted and consultation as required
under the law, CDC has finalized the
materials for serogroup B
meningococcal vaccine. Copies of the
final vaccine information materials for
serogroup B meningococcal vaccine are
available to download from https://
www.cdc.gov/vaccines/hcp/vis/
index.html or https://
www.regulations.gov (see Docket
Number CDC–2015–0059). Final
updated vaccine information materials
for meningococcal ACWY were
published in the Federal Register on
April 20, 2016 (81 FR 23301).
SUMMARY:
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
Beginning no later than
December 1, 2016, each health care
provider who administers serogroup B
meningococcal vaccine to any child or
adult in the United States shall provide
copies of the relevant vaccine
information materials referenced in this
notice, in conformance with the August
9, 2016 CDC Instructions for the Use of
Vaccine Information Statements prior to
providing such vaccinations.
FOR FURTHER INFORMATION CONTACT:
Suzanne Johnson-DeLeon (msj1@
cdc.gov), National Center for
Immunization and Respiratory Diseases,
Centers for Disease Control and
Prevention, Mailstop A–19, 1600 Clifton
Road, NE., Atlanta, Georgia 30329.
SUPPLEMENTARY INFORMATION: The
National Childhood Vaccine Injury Act
of 1986 (Pub. L. 99–660), as amended by
section 708 of Public Law 103–183,
added section 2126 to the Public Health
Service Act. Section 2126, codified at 42
U.S.C. 300aa–26, requires the Secretary
of Health and Human Services to
develop and disseminate vaccine
information materials for distribution by
all health care providers in the United
States to any patient (or to the parent or
legal representative in the case of a
child) receiving vaccines covered under
the National Vaccine Injury
Compensation Program (VICP).
Development and revision of the
vaccine information materials, also
known as Vaccine Information
Statements (VIS), have been delegated
by the Secretary to the Centers for
Disease Control and Prevention (CDC).
Section 2126 requires that the materials
be developed, or revised, after notice to
the public, with a 60-day comment
period, and in consultation with the
Advisory Commission on Childhood
Vaccines, appropriate health care
provider and parent organizations, and
the Food and Drug Administration. The
law also requires that the information
contained in the materials be based on
available data and information, be
presented in understandable terms, and
include:
(1) A concise description of the
benefits of the vaccine,
(2) A concise description of the risks
associated with the vaccine,
(3) A statement of the availability of
the National Vaccine Injury
Compensation Program, and
(4) Such other relevant information as
may be determined by the Secretary.
The vaccines initially covered under
the National Vaccine Injury
Compensation Program were diphtheria,
tetanus, pertussis, measles, mumps,
rubella, and poliomyelitis vaccines.
Since April 15, 1992, any health care
DATES:
E:\FR\FM\08SEN1.SGM
08SEN1
Federal Register / Vol. 81, No. 174 / Thursday, September 8, 2016 / Notices
provider in the United States who
intends to administer one of these
covered vaccines is required to provide
copies of the relevant vaccine
information materials prior to
administration of any of these vaccines.
Since then, the following vaccines have
been added to the National Vaccine
Injury Compensation Program, requiring
use of vaccine information materials for
them as well: Hepatitis B, Haemophilus
influenzae type b (Hib), varicella
(chickenpox), pneumococcal conjugate,
rotavirus, hepatitis A, meningococcal,
human papillomavirus (HPV), and
seasonal influenza vaccines.
Instructions for use of the vaccine
information materials are found on the
CDC Web site at: https://www.cdc.gov/
vaccines/hcp/vis/.
Revised Vaccine Information Materials
The serogroup B meningococcal
vaccine information materials
referenced in this notice were
developed in consultation with the
Advisory Commission on Childhood
Vaccines, the Food and Drug
Administration, and parent and
healthcare provider organizations.
Following consultation and review of
comments submitted, the vaccine
information materials covering
serogroup B meningococcal vaccine
have been finalized and are available to
download from https://www.cdc.gov/
vaccines/hcp/vis/ or https://
www.regulations.gov (see Docket
Number CDC–2015–0059). The Vaccine
Information Statement (VIS) is
‘‘Serogroup B Meningococcal (MenB)
Vaccine: What You Need to Know,’’
publication date August 9, 2016.
With publication of this notice, as of
December 1, 2016, all health care
providers will be required to provide
copies of these updated serogroup B
meningococcal vaccine information
materials prior to immunization in
conformance with CDC’s August 9, 2016
Instructions for the Use of Vaccine
Information Statements.
Dated: September 1, 2016.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
mstockstill on DSK3G9T082PROD with NOTICES
[FR Doc. 2016–21574 Filed 9–7–16; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014
19:34 Sep 07, 2016
Jkt 238001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2015–0029]
Final Revised Vaccine Information
Materials for Polio Vaccine
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
Under the National
Childhood Vaccine Injury Act (NCVIA)
(42 U.S.C. 300aa–26), CDC must develop
vaccine information materials that all
health care providers are required to
give to patients/parents prior to
administration of specific vaccines. On
March 15, 2016, CDC published a notice
in the Federal Register (81 FR 13794)
seeking public comments on proposed
updated vaccine information materials
for polio vaccine and varicella vaccine.
Following review of comments
submitted and consultation as required
under the law, CDC has finalized the
materials for polio vaccine. Copies of
the final vaccine information materials
for polio vaccine are available to
download from https://www.cdc.gov/
vaccines/hcp/vis/ or https://
www.regulations.gov (see Docket
Number CDC–2015–0029). CDC will
publish the final vaccine information
materials for varicella vaccine when
they are completed.
DATES: Beginning no later than
November 1, 2016, each health care
provider who administers polio vaccine
to any child or adult in the United
States shall provide copies of the
relevant vaccine information materials
referenced in this notice, in
conformance with the August 9, 2016
CDC Instructions for the Use of Vaccine
Information Statements prior to
providing such vaccinations.
FOR FURTHER INFORMATION CONTACT:
Suzanne Johnson-DeLeon (msj1@
cdc.gov), National Center for
Immunization and Respiratory Diseases,
Centers for Disease Control and
Prevention, Mailstop A–19, 1600 Clifton
Road NE., Atlanta, Georgia 30329.
SUPPLEMENTARY INFORMATION: The
National Childhood Vaccine Injury Act
of 1986 (Pub. L. 99–660), as amended by
section 708 of Public Law 103–183,
added section 2126 to the Public Health
Service Act. Section 2126, codified at 42
U.S.C. 300aa–26, requires the Secretary
of Health and Human Services to
develop and disseminate vaccine
information materials for distribution by
SUMMARY:
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
62137
all health care providers in the United
States to any patient (or to the parent or
legal representative in the case of a
child) receiving vaccines covered under
the National Vaccine Injury
Compensation Program (VICP).
Development and revision of the
vaccine information materials, also
known as Vaccine Information
Statements (VIS), have been delegated
by the Secretary to the Centers for
Disease Control and Prevention (CDC).
Section 2126 requires that the materials
be developed, or revised, after notice to
the public, with a 60-day comment
period, and in consultation with the
Advisory Commission on Childhood
Vaccines, appropriate health care
provider and parent organizations, and
the Food and Drug Administration. The
law also requires that the information
contained in the materials be based on
available data and information, be
presented in understandable terms, and
include:
(1) A concise description of the
benefits of the vaccine,
(2) A concise description of the risks
associated with the vaccine,
(3) A statement of the availability of
the National Vaccine Injury
Compensation Program, and
(4) Such other relevant information as
may be determined by the Secretary.
The vaccines initially covered under
the National Vaccine Injury
Compensation Program were diphtheria,
tetanus, pertussis, measles, mumps,
rubella, and poliomyelitis vaccines.
Since April 15, 1992, any health care
provider in the United States who
intends to administer one of these
covered vaccines is required to provide
copies of the relevant vaccine
information materials prior to
administration of any of these vaccines.
Since then, the following vaccines have
been added to the National Vaccine
Injury Compensation Program, requiring
use of vaccine information materials for
them as well: Hepatitis B, Haemophilus
influenzae type b (Hib), varicella
(chickenpox), pneumococcal conjugate,
rotavirus, hepatitis A, meningococcal,
human papillomavirus (HPV), and
seasonal influenza vaccines.
Instructions for use of the vaccine
information materials are found on the
CDC Web site at: https://www.cdc.gov/
vaccines/hcp/vis/.
Revised Vaccine Information Materials
The polio vaccine information
materials referenced in this notice were
developed in consultation with the
Advisory Commission on Childhood
Vaccines, the Food and Drug
Administration, and parent and
healthcare provider organizations.
E:\FR\FM\08SEN1.SGM
08SEN1
]]>Agencies
[Federal Register Volume 81, Number 174 (Thursday, September 8, 2016)]
[Notices]
[Pages 62136-62137]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-21574]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2015-0059]
Final Revised Vaccine Information Materials for Serogroup B
Meningococcal Vaccine
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Under the National Childhood Vaccine Injury Act (NCVIA) (42
U.S.C. 300aa-26), CDC must develop vaccine information materials that
all health care providers are required to give to patients/parents
prior to administration of specific vaccines. On October 14, 2015, CDC
published a notice in the Federal Register (80 FR 61819) seeking public
comments on proposed updated vaccine information materials for
meningococcal ACWY and serogroup B meningococcal vaccines. Following
review of comments submitted and consultation as required under the
law, CDC has finalized the materials for serogroup B meningococcal
vaccine. Copies of the final vaccine information materials for
serogroup B meningococcal vaccine are available to download from https://www.cdc.gov/vaccines/hcp/vis/ or https://www.regulations.gov
(see Docket Number CDC-2015-0059). Final updated vaccine information
materials for meningococcal ACWY were published in the Federal Register
on April 20, 2016 (81 FR 23301).
DATES: Beginning no later than December 1, 2016, each health care
provider who administers serogroup B meningococcal vaccine to any child
or adult in the United States shall provide copies of the relevant
vaccine information materials referenced in this notice, in conformance
with the August 9, 2016 CDC Instructions for the Use of Vaccine
Information Statements prior to providing such vaccinations.
FOR FURTHER INFORMATION CONTACT: Suzanne Johnson-DeLeon (msj1@cdc.gov),
National Center for Immunization and Respiratory Diseases, Centers for
Disease Control and Prevention, Mailstop A-19, 1600 Clifton Road, NE.,
Atlanta, Georgia 30329.
SUPPLEMENTARY INFORMATION: The National Childhood Vaccine Injury Act of
1986 (Pub. L. 99-660), as amended by section 708 of Public Law 103-183,
added section 2126 to the Public Health Service Act. Section 2126,
codified at 42 U.S.C. 300aa-26, requires the Secretary of Health and
Human Services to develop and disseminate vaccine information materials
for distribution by all health care providers in the United States to
any patient (or to the parent or legal representative in the case of a
child) receiving vaccines covered under the National Vaccine Injury
Compensation Program (VICP).
Development and revision of the vaccine information materials, also
known as Vaccine Information Statements (VIS), have been delegated by
the Secretary to the Centers for Disease Control and Prevention (CDC).
Section 2126 requires that the materials be developed, or revised,
after notice to the public, with a 60-day comment period, and in
consultation with the Advisory Commission on Childhood Vaccines,
appropriate health care provider and parent organizations, and the Food
and Drug Administration. The law also requires that the information
contained in the materials be based on available data and information,
be presented in understandable terms, and include:
(1) A concise description of the benefits of the vaccine,
(2) A concise description of the risks associated with the vaccine,
(3) A statement of the availability of the National Vaccine Injury
Compensation Program, and
(4) Such other relevant information as may be determined by the
Secretary.
The vaccines initially covered under the National Vaccine Injury
Compensation Program were diphtheria, tetanus, pertussis, measles,
mumps, rubella, and poliomyelitis vaccines. Since April 15, 1992, any
health care
[[Page 62137]]
provider in the United States who intends to administer one of these
covered vaccines is required to provide copies of the relevant vaccine
information materials prior to administration of any of these vaccines.
Since then, the following vaccines have been added to the National
Vaccine Injury Compensation Program, requiring use of vaccine
information materials for them as well: Hepatitis B, Haemophilus
influenzae type b (Hib), varicella (chickenpox), pneumococcal
conjugate, rotavirus, hepatitis A, meningococcal, human papillomavirus
(HPV), and seasonal influenza vaccines. Instructions for use of the
vaccine information materials are found on the CDC Web site at: https://www.cdc.gov/vaccines/hcp/vis/.
Revised Vaccine Information Materials
The serogroup B meningococcal vaccine information materials
referenced in this notice were developed in consultation with the
Advisory Commission on Childhood Vaccines, the Food and Drug
Administration, and parent and healthcare provider organizations.
Following consultation and review of comments submitted, the vaccine
information materials covering serogroup B meningococcal vaccine have
been finalized and are available to download from https://www.cdc.gov/vaccines/hcp/vis/ or https://www.regulations.gov (see Docket
Number CDC-2015-0059). The Vaccine Information Statement (VIS) is
``Serogroup B Meningococcal (MenB) Vaccine: What You Need to Know,''
publication date August 9, 2016.
With publication of this notice, as of December 1, 2016, all health
care providers will be required to provide copies of these updated
serogroup B meningococcal vaccine information materials prior to
immunization in conformance with CDC's August 9, 2016 Instructions for
the Use of Vaccine Information Statements.
Dated: September 1, 2016.
Sandra Cashman,
Executive Secretary, Centers for Disease Control and Prevention.
[FR Doc. 2016-21574 Filed 9-7-16; 8:45 am]
BILLING CODE 4163-18-P
